Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Developments in HIV neuropathogenesis.

Jeffrey A Rumbaugh1, Avindra Nath

  • 1Department of Neurology, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Baltimore, MD 21287, USA. jrumbaug@jhmi.edu

Current Pharmaceutical Design
|March 7, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neurological Manifestations in Adult Survivors of Ebola Virus Disease.

JAMA neurology·2026
Same author

The next phase in Long COVID research: addressing the ethical challenges in trials of disease-modifying treatments.

EClinicalMedicine·2026
Same author

Functional Activity of TDP-43: A Direct Biomarker for ALS.

medRxiv : the preprint server for health sciences·2026
Same author

Designing studies for post-treatment Lyme disease and other infection-associated chronic illnesses.

Brain : a journal of neurology·2026
Same author

Genetic mechanisms underlying host susceptibility to central nervous system viral infections.

Current opinion in infectious diseases·2026
Same author

Downregulation of miRNAs Accompanies Increased HERV-K (HML-2) Expression in Amyotrophic Lateral Sclerosis.

Molecular neurobiology·2026
Same journal

Fentanyl and its Analogs: A Medicinal Chemistry Perspective on Therapeutic Potential and Abuse Liability.

Current pharmaceutical design·2026
Same journal

Acne Vulgaris: Integrating Pathophysiology with Conventional, Herbal, and Nanocarrier-Based Therapeutic Strategies.

Current pharmaceutical design·2026
Same journal

Systems Pharmacology and Pharmaco-Transcriptomic Insights into Bauhinia variegata for Polycystic Ovary Syndrome Management.

Current pharmaceutical design·2026
Same journal

Curcumin and Cognitive Health: Insights from Randomized Controlled Trials.

Current pharmaceutical design·2026
Same journal

Inorganic Materials-integrated Porphyrin for Drug Delivery in Cancer Therapy: Promises, Challenges and Outlooks.

Current pharmaceutical design·2026
Same journal

Precision Nanotechnology in Oral Oncology: From Biomarker-Guided Targeting to AI-Driven Theranostics.

Current pharmaceutical design·2026
See all related articles

Human immunodeficiency virus (HIV) causes neuronal loss and persistent neurological complications, even with treatment. Recent research clarifies HIV neuropathogenesis, paving the way for new therapies.

Area of Science:

  • Neuroscience
  • Virology
  • Immunology

Background:

  • Neurons are rarely infected by HIV, yet neuronal loss is common in HIV patients.
  • Neurological complications persist despite highly active antiretroviral therapy (HAART).
  • HIV-induced neurological damage has significant personal and socioeconomic consequences.

Purpose of the Study:

  • To review the current understanding of HIV neuropathogenesis.
  • To summarize recent research on viral and host factors in HIV-induced neurological disease.
  • To outline a framework for current and future therapeutic trials.

Main Methods:

  • Review of recent scientific literature on HIV neuropathogenesis.
  • Analysis of molecular mechanisms underlying HIV's impact on the nervous system.

Related Experiment Videos

  • Synthesis of knowledge to inform therapeutic strategies.

    • Main Results:

    • Advances in defining molecular mechanisms of HIV-induced nervous system damage.
    • Identification of key viral and host factors mediating neurological disease.
    • Emerging therapeutic options based on a better understanding of neuropathogenesis.

    Conclusions:

    • Understanding HIV neuropathogenesis is crucial for managing neurological complications.
    • Targeting viral and host factors offers promising therapeutic avenues.
    • Future trials should focus on preventing and improving neurological outcomes in HIV patients.